Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran for Malignancy Associated VTE
NCT03240120Phase 3Unknown
- Sponsor
- The University of Hong Kong
- Start
- Sep 2017
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dabigatran in venous thromboembolism (VTE), sponsored by The University of Hong Kong. Primary endpoint: Number of patients with symptomatic VTE at 2 years. Status: unknown.
02
Drugs
dabigatran
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03240120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03240120.